Top Markets
Coin of the day
D. Western Therapeutics Institute, Inc. D. Western Therapeutics Institute, Inc.

D. Western Therapeutics Institute, Inc.

4576
株式のランク #27476
D. Western Therapeutics Institute, Inc. is a biotechnology enterprise focused... D. Western Therapeutics Institute, Inc. is a biotechnology enterprise focused on the research, discovery, and innovation of various pharmaceutical drugs. The company's current portfolio includes GLANATEC and GLA-ALPHA, ophthalmic solutions prescribed for glaucoma and ocular hypertension, as well as DW-1001, another medication for eye conditions. It also provides DWR-2206, a regenerative cell-based product targeting bullous keratopathy, and DW-1002, an ophthalmic surgical aid used for staining membranes like ILM, ALC, ERM, and PVR during cataract operations. In its development pipeline, the company is advancing DW-5LBT, a lidocaine patch designed to alleviate neuropathic pain post-shingles. Additionally, K-321 is progressing through Phase III clinical trials for Fuch endothelial corneal dystrophy, and H-1337, a multi-kinase inhibitor, has commenced Phase IIb trials for glaucoma and ocular hypertension treatment. The firm was established in 1999 and operates from its headquarters in Nagoya, Japan.
株価
$0.5676202
時価総額
$32.62M
変化(1日)
3.57%
変化(1年)
-23.97%
JP
取引 D. Western Therapeutics Institute, Inc. (4576)

カテゴリー

D. Western Therapeutics Institute, Inc.(4576)のP/S比率
2026 時点のP/S比率 TTM: 0
D. Western Therapeutics Institute, Inc. の最新の財務報告および株価によると、現在のP/S比率(TTM)は 0 です。2026 年末時点でのP/S比率は 0 でした。
D. Western Therapeutics Institute, Inc. の P/S 比率の履歴(2026 ~ 2026)
各年末時点のP/S比率
P/S比率 変化
提供された日付のデータは十分ではありません。
同業他社のP/S比率
企業 P/S比率 P/S比率の差
10.17 -
US
11.28 -
US
10.13 -
NL
2.95 -
AU
- -
CH